

CV Dott.ssa Maura Faraci

POSIZIONE RICOPERTA

Direttore del Programma Trapianto di Cellule Staminali Ematologa presso l'Istituto G. Gaslini , Genova

TITOLO DI STUDIO

- Laurea in medicina e chirurgia (1987) con votazione 110/110
- Specialità in Pediatria (1991): con votazione 50/50 lode
- Specialità in Ematologia (2001) con votazione 50/50

Dal 1987 al 1989

Dal 1989 a 1991

Dal 1992 al 1999

Novembre 1999

Dal 2015

Dal Dicembre 2019

- Medico in formazione specialistica presso la clinica pediatrica I
- Medico in formazione specialistica presso l'Emato-oncologia pediatrica Istituto G. Gaslini (IV Divisione di Pediatra) e contratto a tempo determinato nel 1991
- Assunzione a tempo indeterminato presso la Pediatria II (reumatologia- malattie metaboliche ed endocrine) dell' Istituto G. Gaslini
- Trasferimento presso Emato-oncologia pediatrica Istituto G. Gaslini (IV Divisione di Pediatra), Unità di Trapianto di cellule staminali emopoietiche Istituto G. Gaslini
- Responsabile Unità clinica del HSCT
- Direttore del Programma Trapianto di cellule staminali emopoietiche
- Responsabile UOSD Trapianto di Cellule staminali Emopoietiche

ESPERIENZA PROFESSIONALE

- Membership dell' European Bone Marrow Transplantation con attiva partecipazione al Pediatric Working party, Infectious disease Working party e late complication Working party
- Membership of Associazione Italiana di Emato- Oncologia Pediatrica (AIEOP)
- Partecipazione a corsi di formazione sul trattamento delle complicanze acute e croniche post trapianto
- Partecipazione a congressi e studi multicentrici su Graft versus Host disease (trattamento e diagnosi)

Lingua madre: Italiano

Altre lingue	COMPRESIONE	PARLATO	PRODUZIONE SCRITTA
Inglese	A2	A2	B2

Competenze comunicative ▪ Possiedo buone competenze comunicative acquisite durante la mia esperienza lavorativa

Competenze organizzative e gestionali ▪ Attualmente Direttore del programma Trapianto

Competenze digitali ▪ Uso facilmente per la mia attività professionale: Windows, Power Point, Excell

Patente di guida Patente B

ULTERIORI INFORMAZIONI

Publicazioni

- Autrice o coautrice di 150 publications di cui 35 con primo nome (Impact factor totale IF 740, HI Google Scholar 28), come riportato da PubMed-National Library of Medicine website (<http://www.ncbi.nlm.nih.gov>). Sono riportate le pubblicazioni come primo nome:
- Faraci M**, Giardino S, Podestà M, Pierri F et al. HAPLOIDENTICAL α/β T-CELL AND B-CELL STEM CELL TRANSPLANTATION IN SEVERE MEVALONATE KINASE DEFICIENCY. *Rheumatology (Oxford)*. 2021 Jan
- Faraci M**, Ricci E, Bagnasco F et al. Imatinib melylate as second-line treatment of bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation in children. *Pediatr Pulmonol*. 2020 Mar;55(3):631-637.
- Faraci M**, Diesch T, Labopin M, et al Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. *Biol Blood Marrow Transplant*. 2019 May 11.
- Faraci M**, Bertaina A, Dalissier A, Ifversen et al. Solid organ transplantation after hematopoietic stem cell transplantation in childhood: A multicentric retrospective survey. *Am J Transplant*. 2019 Jun;19(6):1798-1805.
- Faraci M**, Calevo MG, Giardino S et al. Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients. *Biol Blood Marrow Transplant*. 2019 Apr;25(4):743-748.
- Faraci M**, Bertaina A, Luksch R et al. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group. *Biol Blood Marrow Transplant*. 2019 Feb;25(2):313-320.
- Faraci M**, Bagnasco F, Leoni M, Giardino S et al. Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases. *Biol Blood Marrow Transplant*. 2018 May;24(5):1088-1093.

9. **Faraci M**, Tinelli C, Lanino E, Giardino S et al. Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years. *Eur J Drug Metab Pharmacokinet*. 2018 Apr;43(2):173-181.
10. **Faraci M**, Giardino S, Bagnasco F et al. Allogeneic hematopoietic stem cell transplantation in congenital disorders: A single-center experience. *Pediatr Transplant*. 2017 Sep;21(6).
11. **Faraci M**, Giardino S, Lanino E et al. Toxic Epidermal Necrolysis-like Reaction After Hematopoietic Stem Cell Transplantation in Children. *J Pediatr Hematol Oncol*. 2017 May;39(4):254-258.
12. **Faraci M**, Matthes-Martin S, Lanino E et al. Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia. *Pediatr Transplant*. 2016 Feb;20(1):158-61.
13. **Faraci M**, Bagnasco F, Giardino S et al. Intensive care unit admission in children with malignant or nonmalignant disease: incidence, outcome, and prognostic factors: a single-center experience. *J Pediatr Hematol Oncol*. 2014 Oct;36(7):e403-9.
14. **Faraci M**, Zecca M, Pillon M et al Italian Association of Paediatric Haematology and Oncology. Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. *Biol Blood Marrow Transplant*. 2014 Feb;20(2):272-8.
15. **Faraci M**, Caviglia I, Biral E et al. Acute graft-versus-host disease in pediatric allogeneic hematopoietic stem cell transplantation. Single-center experience during 10 yr. *Pediatr Transplant*. 2012 Dec;16(8):887-93.
16. **Faraci M**, Morana G, Bagnasc et al. Magnetic resonance imaging in childhood leukemia survivors treated with cranial radiotherapy: a cross sectional, single center study. *Pediatr Blood Cancer*. 2011 Aug;57(2):240-6.
17. **Faraci M**, Lanino E, Morreale G et al. Bacteremias and invasive fungal diseases in children receiving etanercept for steroid-resistant acute GVHD. *Bone Marrow Transplant*. 2011 Jan;46(1):159-60.
18. **Faraci M**, Caviglia I, Morreale G et al. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children. *Bone Marrow Transplant*. 2010 Jun;45(6):1052-5.
19. **Faraci M**, Bagnasco F, Corti P et al AIEOP-HSCT Group. Osteochondroma after hematopoietic stem cell transplantation in childhood. An Italian study on behalf of the AIEOP-HSCT group. *Biol Blood Marrow Transplant*. 2009 Oct;15(10):1271-6.
20. **Faraci M**, Lanino E, Micalizzi C et al. Unrelated hematopoietic stem cell transplantation for Cernunnos-XLF deficiency. *Pediatr Transplant*. 2009 Sep;13(6):785-9.
21. **Faraci M**, Cuzzubbo D, Lanino et al. Low dosage cidofovir without probenecid as treatment for BK virus hemorrhagic cystitis after hemopoietic stem cell transplant. *Pediatr Infect Dis J*. 2009 Jan;28(1):55-7.
22. **Faraci M**, Cappelli B, Lanino E et al.. Hepatitis B reactivation in allogeneic hemopoietic stem cell transplantation setting: a pediatric experience. *Pediatr Transplant*. 2009 Nov;13(7):923-6.
23. **Faraci M**, Dini G; Paediatric Diseases Working Party. Assessing the risk of transplant-related complications and individually tailoring the HSCT procedure in children and adolescents--is it possible? *Bone Marrow Transplant*. 2008 Oct;42 Suppl 2:S90-6.
24. **Faraci M**, Békássy AN, De Fazio V et al. EBMT Paediatric and Late Effects Working Parties. Non-endocrine late complications in children after allogeneic haematopoietic SCT. *Bone Marrow Transplant*. 2008 Jun;41 Suppl 2:S49-57.
25. **Faraci M**, Morreale G, Boeri E et al. Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria. *Pediatr Transplant*. 2008 Feb;12(1):117-20
26. **Faraci M**, Cuzzubbo D, Micalizzi C et al. Allogeneic bone marrow transplantation for Pearson's syndrome. *Bone Marrow Transplant*. 2007 May;39(9):563-5. Epub 2007 Mar 5.
27. **Faraci M**, Cappelli B, Morreale G et al. Nitazoxanide or CD3+/CD4+ lymphocytes for recovery from severe Cryptosporidium infection after allogeneic bone marrow transplant? *Pediatr Transplant*. 2007 Feb;11(1):113-6.
28. **Faraci M**, Calevo MG, Lanino E et al. AIEOP-SCT Group. Osteonecrosis after
29. allogeneic stem cell transplantation in childhood. A case-control study in Italy. *Haematologica*. 2006 Aug;91(8):1096-9.
30. **Faraci M**, Micalizzi C, Lanino E et al. Three consecutive related bone marrow transplants for juvenile myelomonocytic leukaemia. *Pediatr Transplant*. 2005 Dec;9(6):797-800.

31. **Faraci M**, Barra S, Cohen A et al. Very late nonfatal consequences of fractionated TBI in children undergoing bone marrow transplant. *Int J Radiat Oncol Biol Phys*. 2005 Dec 1;63(5):1568-75.
32. 1;63(5):1568-75.
33. **Faraci M**, Dallorso S, Morreale G et al. Surgery for acute graft-versus-host disease of the bowel: description of a pediatric case. *J Pediatr Hematol Oncol*. 2004 Jul;26(7):441-3.
34. **Faraci M**, Lanino E, Dallorso S et al. Mesial temporal sclerosis--a late complication in four allogeneic pediatric recipients with persistent seizures after an acute episode of cyclosporine-A neurotoxicity. *Bone Marrow Transplant*. 2003 May;31(10):919-22.
35. **Faraci M**, Lanino E, Dini G et al. Severe neurologic complications after hematopoietic stem cell transplantation in children. *Neurology*. 2002 Dec 24;59(12):1895-904. Erratum in: *Neurology*. 2003 Mar 25;60(6):1055.

Dott.ssa Maura Faraci

Data e Luogo
Genova 20/03/2024

Dati personali Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".